<DOC>
	<DOCNO>NCT01706679</DOCNO>
	<brief_summary>To evaluate effect maximum therapeutic supratherapeutic dos ATX-101 treatment Fridericia 's correct QT interval ( QTcF ) .</brief_summary>
	<brief_title>Evaluation Effect ATX-101 QT/QTc Intervals</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Males nonpregnant , nonlactating female age 18 65 year ( inclusive ) . Females must negative serum human chorionic gonadotropin ( hCG ) test result sample obtain screening period admission research facility , dose study material . Females postmenopausal status must menses least one year young 55 year age must serum FSH level â‰¥ 35 mIU/mL . Females childbearing potential must agree practice adequate contraception , judgment investigator , course trial . Body Mass Index ( BMI ) range 20 38 kg/m2 ( inclusive ) . Refer Appendix A . Presence sufficient submental fat 25 subcutaneous injection space 1.0cm grid safely administer base investigator 's judgment . Normal vital sign 10 minute rest supine position : Systolic Blood Pressure : 90 mm Hg 140 mm Hg Diastolic Blood Pressure : 45 mm Hg 90 mm Hg Heart Rate : 45 bpm 100 bpm Normal Resting ECG PR Interval : 120 msec 220 msec QRS Duration : &lt; 120 msec QTcF Duration : &lt; 450 msec Serum hemoglobin test result 11.0 g/dL great negative hepatitis B , hepatitis C , HIV test result within 28 day dose study material . Willing able comply understand visit schedule protocolspecified test procedure . Medically able undergo administration study material determine clinical laboratory evaluation obtain within 28 day dose study material investigator identifies clinically significant abnormality . Signed informed consent obtain studyspecific procedure conduct . Any prescription medication take within 14 day ( 5 elimination halflives , whichever long ) Study Day 2 , take overthecounter medication , include topical medication , herbal dietary supplements/remedies within 7 day Study Day 2 , plan concomitant medication study ( except acetaminophen 2 g/day hormonal birth control ) . A history additional risk factor Torsade de Pointes ( e.g . hypokalemia , history drown survival , family history Long QT Syndrome , family history Short QT Syndrome , family history unexplainable early sudden death ) . Participation study investigational drug device within 30 day prior baseline ECG . Any condition , judgment investigator , would place subject undue risk , potentially compromise result interpretation study . Uncontrolled cardiac arrhythmia , example , atrial fibrillation ventricular response rest &gt; 100 beat per minute . Known abnormality cardiac valve ( either stenosis regurgitation ) great moderate severity . Subjects sinus rhythm screening . Hypersensitivity Moxifloxacin History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . Use tobacco nicotinecontaining product within 3 month prior dose . History intervention treat submental fat ( e.g . liposuction , surgery , lipolytic agent ) . History trauma associate chin neck area , judgment investigator may affect evaluation safety treatment . Loose skin neck chin area reduction submental fat may , judgment investigator , result cosmetically unacceptable outcome . Prominent platysmal band rest interfere evaluation submental fat . Evidence cause enlargement submental area localize subcutaneous fat . Any blood donation significant blood loss within 56 day dose study material plasma donation within 7 day Day 1 . A result coagulation test ( PT , PTT ) obtain within 28 day dose study material indicates presence clinically significant bleed disorder . Any medical condition would interfere assessment safety trial would compromise ability subject undergo study procedure give inform consent . Treatment oral anticoagulant ( e.g . warfarin ) within 30 day dose study material . Treatment radio frequency , laser procedure , chemical peel , dermal filler neck chin within 12 month dose study material , botulinum toxin injection neck chin area within 6 month dose study material . History sensitivity component study material . History drug alcohol abuse , judgment investigator , within two year dose study material . Presence positive urine drug alcohol screen test result obtain sample obtain screening period and/or admission research facility confinement period , dose study material . Previous enrollment trial ATX101 . Treatment investigational device agent within 30 day prior baseline ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>